Mounjaro for Weight Loss: Off-Label Use, Evidence, and Monitoring Requirements

Is Mounjaro Approved for Weight Loss?

No. The Mounjaro label covers two uses: improving blood sugar control in adults and children 10 years of age and older with type 2 diabetes, and reducing the risk of major cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) in adults with type 2 diabetes at high risk for those events [1]. Weight loss is not one of them.

Tirzepatide is FDA-approved for weight reduction under the brand name Zepbound, for adults with obesity, or with overweight plus a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity. The Zepbound label starts at 2.5 mg weekly for 4 weeks, then 5 mg, with maintenance doses of 5, 10 or 15 mg weekly for weight reduction.

Off-label use means prescribing a medicine for an indication that is not in its FDA-approved labeling.

What the Weight-Loss Trials Show

SURMOUNT-1 enrolled 2,539 adults with a BMI of 30 or higher, or 27 or higher plus at least one weight-related complication, and no diabetes. Mean starting weight was 104.8 kg. Participants received 5, 10 or 15 mg of tirzepatide or placebo once weekly for 72 weeks, with a 20-week dose-escalation period, alongside diet and activity support [2].

At week 72, mean weight change was -15.0% on 5 mg, -19.5% on 10 mg and -20.9% on 15 mg, versus -3.1% with placebo [2].

SURMOUNT-2 tested tirzepatide in 938 adults with a BMI of 27 or higher and type 2 diabetes (HbA1c 7% to 10%). Weight change at week 72 was -12.8% on 10 mg and -14.7% on 15 mg versus -3.2% on placebo, and 79.2% and 82.8% of those arms lost at least 5% of body weight against 32.5% on placebo [3].

SURMOUNT-4 examined what happens when treatment stops. All 783 participants took open-label tirzepatide for 36 weeks; the 670 who went on to the randomized phase had lost a mean 20.9%. From week 36 to week 88, weight changed by -5.5% in those who kept taking tirzepatide and +14.0% in those switched to placebo [4].

SURMOUNT-5 compared tirzepatide with semaglutide directly in 751 adults with obesity and no diabetes: -20.2% versus -13.7% at 72 weeks, with waist circumference down 18.4 cm versus 13.0 cm [5].

Is the weight lost mostly muscle?

No. A body-composition substudy of SURMOUNT-1 used DXA scans in 160 participants. Over 72 weeks, tirzepatide reduced body weight by 21.3%, fat mass by 33.9% and lean mass by 10.9%, against 5.3%, 8.2% and 2.6% with placebo. About 75% of the weight lost was fat mass and about 25% was lean mass, the same split seen with placebo [6]. DXA cannot separate muscle from other lean tissue, and the substudy was small.

How Tirzepatide Lowers Weight

Tirzepatide activates both the GIP receptor and the GLP-1 receptor. It decreases calorie intake, likely through appetite, and it delays gastric emptying. That delay is largest after the first dose and diminishes over time [1].

Dosing Used for Weight Loss

The Mounjaro label starts everyone at 2.5 mg once weekly. The dose goes up in 2.5 mg steps, no sooner than 4 weeks apart, when more effect is needed; the adult maximum is 15 mg weekly and the maximum in children 10 and older is 10 mg weekly [1]. In the label that escalation is framed around blood sugar control, since type 2 diabetes is the labeled use. The doses tested for weight loss were 5, 10 and 15 mg once weekly [2], and 2.5 mg appears in the label only as the starting dose [1].

The Mounjaro label says that a missed dose should be given as soon as possible within 4 days (96 hours); if more than 4 days have passed, the label says to skip the missed dose and give the next one on the regularly scheduled day. The label also allows changing the weekly dosing day when two doses are at least 3 days (72 hours) apart, and describes injecting into the abdomen, the thigh, or the back of the upper arm when another person gives the injection, rotating sites with each dose [1]. The label gives a vial, a single-dose prefilled pen and a single-patient-use KwikPen as examples of presentations, and says patients need training appropriate to the presentation they receive [1].

What Monitoring Does the Label Describe?

The Mounjaro label contains no monitoring schedule written for weight loss. What it does describe is monitoring tied to named risks [1]:

• Kidney function. Postmarketing reports describe acute kidney injury, sometimes requiring dialysis, mostly in patients whose nausea, vomiting or diarrhea led to dehydration. The label says to monitor renal function in patients reporting reactions that could cause volume depletion, especially during dose initiation and escalation [1].
• Pancreatitis. Acute pancreatitis, including hemorrhagic and necrotizing cases, has been reported. The label says to watch for persistent severe abdominal pain, sometimes radiating to the back, and to discontinue the drug if pancreatitis is suspected [1].
• Low blood sugar with insulin or sulfonylureas. Combining tirzepatide with insulin or an insulin secretagogue such as a sulfonylurea raises the risk of hypoglycemia, including severe hypoglycemia, and the label says a reduction in the insulin or sulfonylurea dose may be necessary [1].
• Gallbladder disease. Acute gallbladder events were reported in 0.6% of tirzepatide-treated adults versus 0% on placebo in the adult placebo-controlled trials; the label says suspected gallstones call for gallbladder studies and follow-up [1].
• Diabetic retinopathy. In patients with a history of retinopathy, the label calls for monitoring for progression, since temporary worsening has been reported with rapid improvement in glucose control [1].
• Thyroid C-cell tumors. The boxed warning covers thyroid C-cell tumors in rats; whether tirzepatide causes them in humans is unknown. The label says routine calcitonin testing or thyroid ultrasound is of uncertain value, and asks that patients be told which symptoms to report: a neck mass, difficulty swallowing, difficulty breathing, or persistent hoarseness [1].
• Oral contraceptives. Tirzepatide can reduce the effectiveness of oral hormonal contraceptives through delayed gastric emptying, with the largest effect after the first dose. The label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose increase; hormonal methods that are not taken by mouth should not be affected [1].
• Stomach emptying and procedures. The label says the drug is not recommended in people with severe gastroparesis, and asks patients to inform healthcare providers of planned surgeries or procedures, given reports of pulmonary aspiration during general anesthesia or deep sedation with GLP-1 receptor agonists [1].

Side Effects in the Trials

In the Mounjaro label's pool of two placebo-controlled trials in adults with type 2 diabetes (718 patients treated with Mounjaro, mean exposure 36.6 weeks), the common reactions at 15 mg versus placebo were nausea (18% vs 4%), diarrhea (17% vs 9%), vomiting (9% vs 2%), constipation (7% vs 1%), decreased appetite (11% vs 1%), dyspepsia (5% vs 3%) and abdominal pain (5% vs 4%) [1]. Severe gastrointestinal reactions occurred in 1.3% on 5 mg, 0.4% on 10 mg and 1.2% on 15 mg versus 0.9% on placebo; treatment was stopped for gastrointestinal reactions in 3.0%, 5.4% and 6.6% versus 0.4% [1]. Most nausea, vomiting and diarrhea occurred during dose escalation and eased over time, and the label states that rates from different trials cannot be compared directly [1].

Compounded Tirzepatide

FDA declared the tirzepatide shortage resolved on 2024-12-19, and the transition periods for compounders ended in early 2025: for state-licensed pharmacies after a court denied a preliminary injunction on 2025-03-05, and for outsourcing facilities on 2025-03-19. Since then, a compounded product that is essentially a copy of the approved drug is permitted only if it is not made regularly or in inordinate amounts (FDA says it does not intend to act against four or fewer such prescriptions per calendar month), or if the prescriber documents a significant difference for an identified patient [7].

Compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before marketing. As of 2026-05-31, FDA had received more than 730 adverse event reports for compounded tirzepatide, a count the agency says likely understates the problem [8]. In April 2026, FDA proposed to exclude tirzepatide from the list of bulk substances outsourcing facilities may compound with, finding no clinical need. Public comment ran to 2026-06-29; this is a proposal, not a final decision [9].

Contraindications, Pregnancy and Lactation

The label contraindicates tirzepatide in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and in anyone with a known serious hypersensitivity to tirzepatide or an excipient; anaphylaxis and angioedema have been reported [1].

In pregnancy, the label says tirzepatide should be used only if the potential benefit justifies the potential risk to the fetus, and notes that animal studies showed reduced fetal growth and fetal abnormalities at clinically relevant exposures [1]. In a single-dose study of 11 lactating women, tirzepatide was undetectable or low in breast milk; there are no data on the breastfed infant or on milk production [1].